Payment overview · 2025
General Payments
$539.49
28 reported records · 12 companies
Healthcare provider profile · identity verified
Seth T Wagner, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · DALTON, GA · NPI 1659506277
Verified facts
What the public records show
CMS Open Payments records show Seth T Wagner, D.O. received $539.49 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.58 | 25.7% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $70.68 | 13.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.01 | 12.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.21 | 10.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.93 | 8.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.36 | 5.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.88 | 5.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.77 | 5.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.01 | 3.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.80 | 3.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.26 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.00 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $539.49 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.86 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.86 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $70.68 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.01 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.01 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.72 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.68 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 157 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
157 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
135 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 883 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 92 |
| Omeprazole | Omeprazole | 363 | 95 |
| Lisinopril | Lisinopril | 337 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 86 |
| Gabapentin | Gabapentin | 250 | 68 |
| Metformin Hcl | Metformin Hcl | 246 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 242 | 66 |
| Montelukast Sodium | Montelukast Sodium | 223 | 51 |
| Potassium Chloride | Potassium Chloride | 222 | 53 |
| Losartan Potassium | Losartan Potassium | 211 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 40 |
| Sertraline Hcl | Sertraline Hcl | 167 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 44 |
| Glipizide Er | Glipizide | 164 | 41 |
| Ozempic | Semaglutide | 159 | 25 |
| Mounjaro | Tirzepatide | 157 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 143 | 25 |
| Trulicity | Dulaglutide | 135 | 21 |
| Simvastatin | Simvastatin | 131 | 37 |
| Carvedilol | Carvedilol | 128 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 32 |
| Furosemide | Furosemide | 124 | 40 |
| Clonazepam | Clonazepam | 123 | 44 |
| Meloxicam | Meloxicam | 122 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 42 |
| Trazodone Hcl | Trazodone Hcl | 112 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 24 |
| Eliquis | Apixaban | 97 | 20 |
| Allopurinol | Allopurinol | 96 | 24 |
| Jardiance | Empagliflozin | 96 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 91 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 26 |
| Cephalexin | Cephalexin | 86 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Alendronate Sodium | Alendronate Sodium | 81 | 22 |
| Metformin Hcl Er | Metformin Hcl | 80 | 20 |
| Finasteride | Finasteride | 79 | 19 |
| Irbesartan | Irbesartan | 78 | 12 |
| Azelastine Hcl | Azelastine Hcl | 75 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 75 | 17 |
| Tramadol Hcl | Tramadol Hcl | 71 | 26 |
| Celecoxib | Celecoxib | 67 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Pregabalin | Pregabalin | 65 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 15 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Fenofibrate | Fenofibrate | 60 | 17 |
| Mirtazapine | Mirtazapine | 58 | 16 |
| Bupropion Xl | Bupropion Hcl | 57 | 16 |
| Famotidine | Famotidine | 57 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 19 |
| Lorazepam | Lorazepam | 55 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 47 |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Prednisone | Prednisone | 38 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 13 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 26 |
| Temazepam | Temazepam | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Azithromycin | Azithromycin | 22 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Naproxen | Naproxen | 22 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Diazepam | Diazepam | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $539.49 · 28 records | Novo Nordisk Inc | Auvelity, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INCEPTIV, Korlym, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error